[2025-10-01T19:48:27.329962] [QUERYOME] Starting research for query 666: 'Instructions:
 Answer the question below. First, respond with the single best option letter (A, B, C, or D). Then provide a concise reasoning (1–3 sentences). Use both the retrieved evidence and your own medical knowledge to choose the most accurate answer.

Question:
Which of the following drug is commonly used in treatment for cancer associated thromboembotismt

Options:
A. Low molecular weight heparin
B. anti-thrombin III inhibitors
C. Direct Xainhibitors
D. Warfarin'
[2025-10-01T19:48:27.374335] [PI] Starting research for query: 'Instructions:
 Answer the question below. First, respond with the single best option letter (A, B, C, or D). Then provide a concise reasoning (1–3 sentences). Use both the retrieved evidence and your own medical knowledge to choose the most accurate answer.

Question:
Which of the following drug is commonly used in treatment for cancer associated thromboembotismt

Options:
A. Low molecular weight heparin
B. anti-thrombin III inhibitors
C. Direct Xainhibitors
D. Warfarin'
[2025-10-01T19:48:27.377459] Saving text to bench_final/run1/medmcqa/medmcqa_2226/pi_initial_prompt.txt
[2025-10-01T19:48:27.382215] [PI] Calling o3 for initial analysis...
[2025-10-01T19:48:37.563172] [PI] Reasoning iteration 1
[2025-10-01T19:48:37.564763] [PI reasoning] **Examining cancer thromboembolism treatment**

The user is asking about the best drug for treating cancer-associated thromboembolism. Historically, low molecular weight heparin (LMWH) is preferred over warfarin due to its better efficacy and lower bleeding risk. Although direct oral anticoagulants (DOACs) like apixaban and rivaroxaban are now considered, LMWH remains commonly recommended, especially for the first few months of treatment. For this exam-style question, the answer would be LMWH, supported by guidelines from CHEST and ASCO.
[2025-10-01T19:48:37.567490] [PI] Executing function call 1: hybrid_search
[2025-10-01T19:48:37.569243] [PI] Function arguments: {'query': 'cancer associated thrombosis treatment low molecular weight heparin preferred over warfarin CLOT trial dalteparin', 'k': 5, 'faiss_weight': 0.6, 'bm25_weight': 0.4, 'use_rrf': True}
[2025-10-01T19:48:37.571875] Saving JSON to bench_final/run1/medmcqa/medmcqa_2226/pi_iteration_1_tool_call_2_hybrid_search.json
[2025-10-01T19:48:38.947804] [PI] Function hybrid_search executed successfully
[2025-10-01T19:48:38.949797] Saving JSON to bench_final/run1/medmcqa/medmcqa_2226/pi_iteration_1_tool_result_2_hybrid_search.json
[2025-10-01T19:48:38.957418] [PI] Continuing reasoning with 1 function responses...
[2025-10-01T19:48:42.582677] [PI] Reasoning iteration 2
[2025-10-01T19:48:42.584059] [PI] No function calls found in response
[2025-10-01T19:48:42.586508] [PI] No more function calls - research complete
[2025-10-01T19:48:42.587690] Saving text to bench_final/run1/medmcqa/medmcqa_2226/pi_final_answer.txt
[2025-10-01T19:48:42.591548] [QUERYOME] Query completed successfully
